stockrow
Monday 9 November 2026
Export BLSM’s income statement to Excel — free account
BlossomHill Therapeutics, Inc.
BLSM
14.24
0.74
+5.48%
Follow BLSM
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | — | — | (31) | (61) | (68) | +97.3% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (31) | (61) | (68) | +97.3% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | — | — | (13.40) | (24.84) | (26.79) | +85.3% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (13.72) | (19.25) | (23.69) | +40.3% | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.04) | (0.44) | (0.37) | +988.8% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (13.76) | (19.68) | (24.06) | +43.1% | ||||||
| Book value | — | — | — | — | — | — | — | — | (31.83) | 51.31 | 30.23 | n/m | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 2 | 2 | 3 | +6.5% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (31) | (47) | (64) | +49.4% | |||||
| Capex | — | — | — | — | — | — | — | — | 0 | (1) | (1) | +1,059.8% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (32) | (48) | (65) | +52.3% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 97 | 123 | 82 | +26.6% | |||||
| Net debt | — | — | — | — | — | — | — | — | (100) | (137) | (95) | +36.5% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (73) | 125 | 82 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (44.90) | 0.00 | (44.9) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 59.19 | 0.00 | +59.2 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 63 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | — | 0.00 | — | — | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 2 Nov 2026
BlossomHill Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BLSM BlossomHill Therapeutics, Inc. | $429.1M | — (loss-making) | — | — | n/m | — | — | 0.00% | |
| RLMD Relmada Therapeutics, Inc. | $416.0M | — (loss-making) | — | — | n/m | −50.06% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ASMB Assembly Biosciences, Inc. | $415.8M | — (loss-making) | — (loss-making) | +38.94% (above 0%: growing) | n/m | +7.58% (above 0%: growing) | 100.00% | (47.44%) | Compare |
| CRMD CorMedix Inc | $414.7M | 2.2× | 10.8× | +156.52% (above 0%: growing) | +13.79% (above 0%: growing) | +185.90% (above 0%: growing) | 75.66% | 42.10% | Compare |
| TECX Tectonic Therapeutic, Inc. | $411.7M | — (loss-making) | — | — | n/m | −46.69% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PRTA Prothena Corporation plc | $409.3M | — (loss-making) | 76.4× | −74.33% (below 0%: shrinking) | n/m | +70.34% (above 0%: growing) | 100.00% | (3,035.65%) | Compare |
| ALT Altimmune, Inc. | $404.6M | — (loss-making) | — (loss-making) | +520.00% (above 0%: growing) | n/m | −25.27% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| EDIT Editas Medicine, Inc. | $394.7M | — (loss-making) | — (loss-making) | +232.31% (above 0%: growing) | n/m | +40.72% (above 0%: growing) | 100.00% | (156.05%) | Compare |
| ALLO Allogene Therapeutics, Inc. | $359.3M | — (loss-making) | — (loss-making) | +20,990.91% (above 0%: growing) | n/m | +17.73% (above 0%: growing) | 100.00% | (1,011.21%) | Compare |
| Median of peers | $410.5M | — | — | +194.42% | — | +12.66% | 100.00% | (23.72%) |